Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-line Sorafenib in Randomized Controlled Trials

Conclusion: The median OS of patients with advanced HCC treated with sorafenib has improved significantly over 15 years . At the same time, the median duration of therapy with sorafenib has decreased. The reason for these findings was not explained by changing demographics of patients enrolled in these trials and has implications for ongoing clinical trials.
Source: Gastrointestinal Tumors - Category: Gastroenterology Source Type: research